Onvansertib Fumarate is a small molecule commercialized by Cardiff Oncology, with a leading Phase II program in Metastatic Colorectal Cancer. According to Globaldata, it is involved in 14 clinical trials, of which 5 were completed, 8 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Onvansertib Fumarate’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Onvansertib Fumarate is expected to reach an annual total of $231 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Onvansertib Fumarate Overview
Onvansertib fumarate (PCM-075) is under development for the treatment of pancreatic ductal adenocarcinoma, chronic myelomonocytic leukemia and advanced or metastatic solid tumors including triple negative breast cancer, small-cell lung cancer, ampullary cancer, skin cancer and hormone refractory (castration-resistant, androgen-independent) prostate cancer. The drug candidate is administered through the oral route. The drug candidate is a 4,5-dihydro-1H-pyrazolo[4,3- h]quinazoline derivative. The drug candidate is a first in class third generation drug acts by targeting Polo-like-kinase 1 (PLK1). It was also under development for adrenocortical carcinoma (adrenal cortex cancer),non-Hodgkin lymphoma and myelodysplastic syndrome.
It was also under development for the treatment of Chronic Myelomonocytic Leukemia (CMML), ovarian cancer, lung cancer, prostate cancer, colorectal cancer, Head And Neck Cancer, Pancreatic Cancer, hepatocellular cancer, sarcomas relapsed or refractory acute myeloid leukemia and medulloblastoma.
Cardiff Oncology Overview
Cardiff Oncology (Cardiff) is a clinical-stage biotechnology company. It is dedicated to developing novel therapies by inhibiting Polo-like kinase 1 (PLK1), targeting significant unmet medical needs in cancer. The company’s lead product candidate, onvansertib, specifically targets PLK1, a well-established target in cancer therapy. Cardiff is advancing various clinical trials, including the Phase 2 CRDF-004 trial for first-line RAS-mutated metastatic colorectal cancer (mCRC) and the TROV-054 trial for second-line KRAS-mutated mCRC. It is also investigating onvansertib for metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple-negative breast cancer, exploring various combination therapies. Cardiff is headquartered in San Diego, California, the US.
The company reported revenues of (US Dollars) US$0.5 million for the fiscal year ended December 2023 (FY2023), an increase of 26.4% over FY2022. The operating loss of the company was US$45.4 million in FY2023, compared to an operating loss of US$39.9 million in FY2022. The net loss of the company was US$41.4 million in FY2023, compared to a net loss of US$38.7 million in FY2022.
The company reported revenues of US$0.2 million for the second quarter ended June 2024, a decrease of 20.5% over the previous quarter.
For a complete picture of Onvansertib Fumarate’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.